Azadeh Razmandi
Optometrist · Houston, TXNPI 1053482687
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,840 of the $13,246 with a category attached, or 66.7%. 22 manufacturers reported payments, led by Pfizer at 27.9% of the total. Reporting peaked in 2021 at $4,485 and has fallen 68.3% since, to $1,424 in 2025. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $179.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Bausch & Lomb Americas Inc.$2K
- Visioneering Technologies, Inc.$1K
- Sun Pharmaceutical Industries Inc.$998
- Bausch & Lomb, A Division Of Bausch Health US, LLC$970
- Alcon$704
- plus $4K from 16 others
Across 3 payments — averaging $1246.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
What the payments were for
- Consulting fees$4854%
- Speaking & faculty fees$3,70028%
- Food & beverage$8,84067%
- Entertainment$2212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $3,700 |
| Bausch & Lomb Americas Inc. | 16 | $1,654 |
| Visioneering Technologies, Inc. | 1 | $1,000 |
| Sun Pharmaceutical Industries Inc. | 9 | $998 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $970 |
| Alcon | 6 | $704 |
| Immunogen, Inc. | 2 | $657 |
| Tarsus Pharmaceuticals, Inc. | 6 | $614 |
| Lumenis BE Inc | 1 | $442 |
| Glaukos Corporation | 3 | $346 |
| AbbVie(2 entities) | 3 | $331 |
| Optos, Inc. | 4 | $315 |
| Johnson & Johnson Vision Care, Inc. | 2 | $274 |
| Dompe US, Inc. | 2 | $247 |
| Biotissue Holdings Inc. | 2 | $183 |
| Amgen | 1 | $143 |
| Ocular Therapeutix, Inc. | 1 | $125 |
| Carl Zeiss Meditec USA, Inc. | 1 | $123 |
| LKC Technologies, Inc. | 1 | $119 |
| Kala Pharmaceuticals, Inc. | 1 | $112 |
| Sight Sciences, Inc. | 1 | $100 |
| Aerie Pharmaceuticals, Inc. | 1 | $91 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRAFTOVI$3,700
- MEKTOVI$3,700
- CEQUA$733
- Elahere$657
- MIEBO$572
- INFUSE$567
- TOTAL30$501
- optilight$442
- LOTEMAX SM$329
- PANORAMIC OPHTHALMOSCOPE$278
- OCT OPHTHALMOSCOPE$278
- Acuvue$274
- XDEMVY$247
- Oxervate$247
- VYZULTA$244
- XIIDRA$241
- ULTRA MULTIFOCAL TORIC$225
- TEPEZZA$143
- NFC-700$139
- Photrexa Viscous and Photrexa$135
How this compares
$13,246 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,125 |
| Latanoprost | 79 | $947 |
| Timolol Maleate | 30 | $459 |
| ErythromycinErythromycin Base | 14 | $207 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Houston
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
- Maria WalkerHouston$128K
- Seema NandaHouston$87K
- Danica MarrelliHouston$87K
- Richard BakerHouston$78K
- Karen LeeHouston$71K
- Nishi MehdirattaHouston$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.